Onconetix (ONCO) Share-based Compensation Growth (1y) (2022 - 2026)
Onconetix (ONCO) Share-based Compensation Growth (1y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 71.86% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -3.46% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -7.69% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -8.89% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -22.43% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 11.71% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -4.01% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Onconetix | 1.44 Mn | -4.50 Mn | 4,303.00 | -76.25% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -76.25% |
| Mar 31, 2026 | -23.76% |
| Dec 31, 2025 | -98.79% |
| Sep 30, 2025 | -78.54% |
| Jun 30, 2025 | 4,097.68% |
| Mar 31, 2025 | -44.43% |
| Dec 31, 2024 | 6.38% |
| Sep 30, 2024 | -56.70% |
| Jun 30, 2024 | -100.28% |
| Mar 31, 2024 | -71.63% |
| Dec 31, 2023 | 121.52% |
| Sep 30, 2023 | -68.04% |
| Jun 30, 2023 | -81.15% |
| Mar 31, 2023 | 859.95% |
| Dec 31, 2022 | -6,435.14% |
| Sep 30, 2022 | 1,025.32% |
| Jun 30, 2022 | 4,043.65% |
| Mar 31, 2022 | -53.66% |